Clasp Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $150M
Overview
A biotech developing precision T-cell engagers that target dual tumor antigens for safer, more effective cancer therapy.
OncologyImmunology
Technology Platform
A proprietary platform for developing bispecific T-cell engagers that require binding to two distinct tumor-associated antigens, creating an 'AND-gate' for highly selective cancer cell killing.
Funding History
1Total raised:$150M
Venture$150M
Opportunities
Potential to redefine the safety standard for T-cell engagers, enabling broader use in solid tumors and outpatient settings.
Risk Factors
Risk that suitable, tumor-exclusive antigen pairs are not found for major cancers, or that the dual-targeting approach compromises therapeutic potency.
Competitive Landscape
Enters a crowded bispecific antibody field but differentiates through its dual-antigen requirement for activation, aiming for a superior safety profile.